IMPACT OF UNCONTROLLED HYPERTENSION ON PATIENT REPORTED QUALITY OF LIFE: RESULTS FROM A REAL-WORLD SURVEY
Author(s)
Alba Sánchez-Viñas, MSc1, Jieling Chen, PhD2, Evi Germeni, PhD3, James Jackson, BA4, Sophie Barlow, MSc4, Tamara Mensah, BSc4, Lucy Hargreaves, BSc4, Juan Jose Garcia Sanchez, BSc, MSc, PharmD1.
1AstraZeneca, Barcelona, Spain, 2AstraZeneca, Geithersburg, MD, USA, 3University of Glasgow, Glasgow, United Kingdom, 4Adelphi Real World, Bollington, United Kingdom.
1AstraZeneca, Barcelona, Spain, 2AstraZeneca, Geithersburg, MD, USA, 3University of Glasgow, Glasgow, United Kingdom, 4Adelphi Real World, Bollington, United Kingdom.
OBJECTIVES: To compare patients with controlled vs. uncontrolled hypertension to understand the difference in impact on health-related quality of life.
METHODS: Data were drawn from the Adelphi Real World Hypertension Disease Specific Programme™, a real-world, cross-sectional survey conducted in the United States (2025-26). Patients were segmented into two groups for analysis: controlled hypertension (C-HTN) and uncontrolled hypertension, (U-HTN) defined as blood pressure ≥140/90mmHg or receiving 4 or more antihypertensive drugs. Physicians reported on patient demographics, symptoms and comorbidities. Quality of life was reported by patients using the EuroQol five-dimension, five-level (EQ5D-5L) questionnaire and visual analogue scale (VAS). Patient groups were compared using bivariate tests and mixed effects linear regression was used to compare patient groups controlling for age, sex, BMI and number of comorbidities.
RESULTS: Data was available for 306 patients; 99 had C-HTN and 207 had U-HTN. Mean age was 59.4 and 64.4% were male. Patients with U-HTN were more likely than patients with C-HTN to experience a higher number of symptoms (0.43 vs 0.18 [p<0.005]), in particular fatigue (10.6% vs. 3.0% [p<0.005]) and a higher number of comorbidities (2.52 vs. 1.70 [p<0.005], including anxiety (16.4% vs. 6.1% [p<0.005]. When adjusting for confounders (age, sex, BMI, number of comorbidities), regression analysis demonstrated that patients with U-HTN were associated with a significantly worse EQ5D utility score, compared with patients with C-HTN (coefficient: -0.083; 95% confidence interval (CI): -0.118, -0.047; p<0.001). Furthermore, patients with U-HTN reported a significantly lower overall health rating on the EQ-5D VAS (coefficient: -4.89; 95% CI: -8.41, -1.37; p=0.007).
CONCLUSIONS: Uncontrolled hypertension is associated with substantially lower outcomes in health-related quality of life, independent of age, sex, BMI, and number of comorbid conditions. These findings highlight the importance of achieving blood pressure control as part of holistic efforts to optimise patient outcomes across multiple dimensions of health.
METHODS: Data were drawn from the Adelphi Real World Hypertension Disease Specific Programme™, a real-world, cross-sectional survey conducted in the United States (2025-26). Patients were segmented into two groups for analysis: controlled hypertension (C-HTN) and uncontrolled hypertension, (U-HTN) defined as blood pressure ≥140/90mmHg or receiving 4 or more antihypertensive drugs. Physicians reported on patient demographics, symptoms and comorbidities. Quality of life was reported by patients using the EuroQol five-dimension, five-level (EQ5D-5L) questionnaire and visual analogue scale (VAS). Patient groups were compared using bivariate tests and mixed effects linear regression was used to compare patient groups controlling for age, sex, BMI and number of comorbidities.
RESULTS: Data was available for 306 patients; 99 had C-HTN and 207 had U-HTN. Mean age was 59.4 and 64.4% were male. Patients with U-HTN were more likely than patients with C-HTN to experience a higher number of symptoms (0.43 vs 0.18 [p<0.005]), in particular fatigue (10.6% vs. 3.0% [p<0.005]) and a higher number of comorbidities (2.52 vs. 1.70 [p<0.005], including anxiety (16.4% vs. 6.1% [p<0.005]. When adjusting for confounders (age, sex, BMI, number of comorbidities), regression analysis demonstrated that patients with U-HTN were associated with a significantly worse EQ5D utility score, compared with patients with C-HTN (coefficient: -0.083; 95% confidence interval (CI): -0.118, -0.047; p<0.001). Furthermore, patients with U-HTN reported a significantly lower overall health rating on the EQ-5D VAS (coefficient: -4.89; 95% CI: -8.41, -1.37; p=0.007).
CONCLUSIONS: Uncontrolled hypertension is associated with substantially lower outcomes in health-related quality of life, independent of age, sex, BMI, and number of comorbid conditions. These findings highlight the importance of achieving blood pressure control as part of holistic efforts to optimise patient outcomes across multiple dimensions of health.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR53
Topic
Clinical Outcomes, Patient-Centered Research, Real World Data & Information Systems
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory)